Taku Nakagawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taku Nakagawa has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Akira Sugimoto
Department of Respiratory Medicine, Graduate School of Medicine Osaka Metropolitan University Osaka Japan
14 shared publications - Eriko Tabata
10Department of Respiratory Medicine, Ikeda City Hospital, Ikeda, Osaka, Japan
14 shared publications - Haruko Daga
Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
14 shared publications - Hibiki Udagawa
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
14 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
14 shared publications - Ichiro Nakachi
Department of Respiratory Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan
14 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Phase I and Early Phase II Study of Enhancing Immune Checkpoint Inhibitor Efficacy Using a Mycobacterium tuberculosis Extract Combined with Radiation Therapy in Non-Small Cell Lung Cancer Patients: NEJ046A
BackgroundThe relationship between immunity against infectious pathogens and antitumor immunity has regained attention. In-vivo studies have demonstrated that the antitumor effects of Z-100, extracted from the Mycobacterium tuberculosis Aoyama strain and containing peptidoglycans, are mediated by CD8+ T cell infiltration into tumors. This study aimed to investigate the immunomodulatory effects of Z-100 in combination with immune checkpoint inhibitors (ICIs) in humans.MethodsPatients with advanced NSCLC who had received ICIs and experienced disease progression within the preceding 3 months were enrolled in this prospective study. While continuing the same ICI therapy, patients received palliative radiotherapy (RT) at a total dose of approximately 30 Gy (3 Gy × 10 fractions) with subcutaneous Z-100 administered twice weekly. Tumor response was independently assessed in measurable lesions outside the irradiation field. The primary endpoints were safety and the 9-month progression-free survival (PFS) rate.ResultsA total of 24 patients were enrolled, and 23 patients with an ECOG performance status of 0–1 received the study treatment. Immune-related adverse events (irAEs) occurred in 9 patients (39.1%), most commonly skin disorders (17.4%), interstitial lung disease (8.7%), and colitis (8.7%). Grade 3 toxicities were limited to skin disorder (4.3%) and colitis (4.3%), with no irAE-related deaths observed. 13 patients transitioned from disease progression to stable disease, resulting in a disease control rate of 56.5%. The median PFS was 5.1 months, and the 9-month PFS rate was 15.2% (90% confidence interval: 6.3–36.2%). The median overall survival (OS) after study enrollment was 17.7 months.ConclusionsICI combined with Z-100 and radiotherapy demonstrated acceptable toxicity, and the NEJ046A study suggests a proof-of-concept, potential immunomodulatory effects of RT combined with Z-100 under ICI treatment.
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPhase I and Early Phase II Study of Enhancing Immune Checkpoint Inhibitor Efficacy Using a Mycobacterium tuberculosis Extract Combined with Radiation Therapy in Non-Small Cell Lung Cancer Patients: NEJ046A
BackgroundThe relationship between immunity against infectious pathogens and antitumor immunity has regained attention. In-vivo studies have demonstrated that the antitumor effects of Z-100, extracted from the Mycobacterium tuberculosis Aoyama strain and containing peptidoglycans, are mediated by CD8+ T cell infiltration into tumors. This study aimed to investigate the immunomodulatory effects of Z-100 in combination with immune checkpoint inhibitors (ICIs) in humans.MethodsPatients with advanced NSCLC who had received ICIs and experienced disease progression within the preceding 3 months were enrolled in this prospective study. While continuing the same ICI therapy, patients received palliative radiotherapy (RT) at a total dose of approximately 30 Gy (3 Gy × 10 fractions) with subcutaneous Z-100 administered twice weekly. Tumor response was independently assessed in measurable lesions outside the irradiation field. The primary endpoints were safety and the 9-month progression-free survival (PFS) rate.ResultsA total of 24 patients were enrolled, and 23 patients with an ECOG performance status of 0–1 received the study treatment. Immune-related adverse events (irAEs) occurred in 9 patients (39.1%), most commonly skin disorders (17.4%), interstitial lung disease (8.7%), and colitis (8.7%). Grade 3 toxicities were limited to skin disorder (4.3%) and colitis (4.3%), with no irAE-related deaths observed. 13 patients transitioned from disease progression to stable disease, resulting in a disease control rate of 56.5%. The median PFS was 5.1 months, and the 9-month PFS rate was 15.2% (90% confidence interval: 6.3–36.2%). The median overall survival (OS) after study enrollment was 17.7 months.ConclusionsICI combined with Z-100 and radiotherapy demonstrated acceptable toxicity, and the NEJ046A study suggests a proof-of-concept, potential immunomodulatory effects of RT combined with Z-100 under ICI treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Table S1 Patient characteristics in patients with 8 oncogene drivers and squamous cell carcinoma Supplementary Table S2 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay Supplementary Table S3 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay in patients only with brain metastasis Supplementary Table S4 Clinical outcomes of patients treated with a genotype-matched therapy who had oncogenic alterations detected by only plasma cfDNA sequencing.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Table S1 Patient characteristics in patients with 8 oncogene drivers and squamous cell carcinoma Supplementary Table S2 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay Supplementary Table S3 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay in patients only with brain metastasis Supplementary Table S4 Clinical outcomes of patients treated with a genotype-matched therapy who had oncogenic alterations detected by only plasma cfDNA sequencing.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Figure S1. Consort diagram. Supplementary Figure S2. Frequency of the targetable gene alterations detected by plasma cfDNA sequencing (A) and tissue assay (B) in squamous cell carcinoma Supplementary Figure S3. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to patient characteristics. PPA, positive percent agreement. Supplementary Figure S4. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to metastatic site. PPA, positive percent agreement.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Figure S1. Consort diagram. Supplementary Figure S2. Frequency of the targetable gene alterations detected by plasma cfDNA sequencing (A) and tissue assay (B) in squamous cell carcinoma Supplementary Figure S3. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to patient characteristics. PPA, positive percent agreement. Supplementary Figure S4. Positive percent agreement of plasma cfDNA sequencing compared to tissue assay according to metastatic site. PPA, positive percent agreement.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Purpose:We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid).Experimental Design:Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing.Results:Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months.Conclusions:Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA.See related commentary by Jacobsen Skanderup et al., p. 1381
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Purpose:We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid).Experimental Design:Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing.Results:Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months.Conclusions:Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA.See related commentary by Jacobsen Skanderup et al., p. 1381
- Open Access
Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC)
Open AccessProspective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized standard therapies for non-small cell lung cancer (NSCLC)
- 14 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 194, 107894
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)
- 14 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 194, 107894
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)
- Open Access
- 10 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11  (9) , 2501
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.
- 10 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11  (9) , 2501
Open AccessA Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Table S1 Patient characteristics in patients with 8 oncogene drivers and squamous cell carcinoma Supplementary Table S2 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay Supplementary Table S3 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay in patients only with brain metastasis Supplementary Table S4 Clinical outcomes of patients treated with a genotype-matched therapy who had oncogenic alterations detected by only plasma cfDNA sequencing.
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Supplementary Table S1 Patient characteristics in patients with 8 oncogene drivers and squamous cell carcinoma Supplementary Table S2 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay Supplementary Table S3 Detectability of eight oncogenic alterations by plasma cfDNA sequencing compared to tissue assay in patients only with brain metastasis Supplementary Table S4 Clinical outcomes of patients treated with a genotype-matched therapy who had oncogenic alterations detected by only plasma cfDNA sequencing.